Introduction
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of childbearing age and the leading cause of hyperandrogenism (HA) and oligo-anovulation (OA) causing infertility (Norman et al., 2007) .
After many years of controversy, there is now worldwide consensus that the diagnosis of PCOS should follow the so-called Rotterdam classification, which requires at least two criteria out of OA, HA and polycystic ovarian morphology (PCOM) for a diagnosis of PCOS, after the exclusion of differential diagnoses (Rotterdam, 2004a,b) . Although the fundamental principle of this classification remains valid (two of these three criteria required for diagnosis), the specific definition of each item remains controversial (Dewailly, 2016) . This is particularly the case for PCOM, which was initially defined as follicle number per ovary (FNPO) ≥12 and/or ovarian volume ≥10 ml (Balen et al., 2003) . This definition, first proposed in 2003, is now obsolete, at least for FNPO when assessed with the latest generation of ultrasound (U/S) devices, with maximal probe frequencies that exceed 8 MHz. These instruments do not, however, appear to affect the threshold for ovarian volume. A FNPO threshold of 12 with the newer devices and their higher resolution very substantially overestimates PCOM prevalence in the general population. A panel of experts recently addressed this problem and proposed the use of higher in-house thresholds (i.e. 19-25) with the new ultrasound machines (Dewailly et al., 2014b) .
This heterogeneity in the U/S definition of PCOM has prompted some authors to investigate the diagnostic value of the serum antiMüllerian hormone (AMH) assay as a surrogate for FNPO (reviewed in Dewailly et al., 2014a) . Because this hormone is secreted by the granulosa cells of pre-antral and small antral growing follicles, its serum level is tightly correlated with FNPO in women with PCOS (Dewailly et al., 2011; Eilertsen et al., 2012; Iliodromiti et al., 2013) . Accordingly, it could replace U/S, especially when the latter's results are negative. The lack of standardization of the AMH assay has, however, prevented any consensus about a threshold value to define PCOM.
A further issue, beside the technical issues related to U/S and the AMH assay, is whether normal women with asymptomatic PCOM should be included in control groups used to define thresholds for PCOM (Dewailly, 2016) . In our center, we use thresholds drawn from a control group from which women with PCOM were excluded on a non-subjective basis by cluster analysis (Dewailly et al., 2011) . Based on that study, we now use thresholds of 19 follicles for FNPO and 35 pmol/l for the AMH level. Other authors have agreed on these thresholds (Lauritsen et al., 2014) .
The aim of this study was to determine if the serum AMH assay and U/S can be used interchangeably to define PCOM and thus to diagnose the different phenotypes of PCOS according to the Rotterdam classification.
Materials and Methods

Patients
Data were obtained about the PCOS patients retrospectively from a database that had collected clinical, hormonal and ultrasound features prospectively from January 2009 to January 2016 from women referred to our department for OA, HA or both. As this study was retrospective with no intervention, the opinion of the Ethics Committee about the study was not required. The Groupe Nantais d'éthique dans le domaine de la santé (GNEDS) gave its unrestricted approval to the anonymous use of clinical, hormonal and ultrasound records from all patients who had previously given their informed consent.
The study included women aged 18-35 years. They were diagnosed with PCOS according to three different classifications: (i) the standard Rotterdam classification (Rotterdam, 2004b) with at least two out of the three following symptoms: (a) OA, (b) clinical and/or biochemical HA and (c) PCOM defined by an ovarian area ≥5.5 cm 2 (Jonard et al., 2005) and/ or a FNPO ≥ 19 (Dewailly et al., 2011) ; (ii) the same classification adapted to define PCOM by high levels of serum AMH, with a threshold of 35 pmol/l, as previously reported (Dewailly et al., 2011) ; and (iii) the same classification modified to define PCOM by either or both of 'positive U/S' and/or 'positive AMH'. Exclusion criteria were: age <18 or more than 35 years, suspicion of low ovarian reserve (FSH > 12 IU/l), hyperprolactinemia (serum prolactin >20 ng/ml on two separate determinations) or nonclassic 21-hydroxylase deficiency (basal 17-hydroxyprogesterone (17-OHP) >5 ng/ml and/or post-adrenocorticotrophic hormone-stimulated value >12 ng/ml). Ovarian or adrenal tumors were ruled out based on serum total testosterone (TT) or dehydroepiandrosterone sulfate levels lower than 1.5 ng/ml or 15 μmol/l, respectively. Women with congenital or acquired hypothalamic amenorrhea were also excluded, as were those with at least one follicle with a diameter >9 mm at U/S or a serum estradiol (E 2 ) level >80 pg/ml. Finally, we excluded pregnant and breastfeeding women, and hormonal contraceptive users.
Investigations
The same procedure was followed throughout the study period. Clinical, hormonal and ultrasound examinations were performed on the same day, in the early follicular phase (between Day 2 and Day 5) of a spontaneous cycle or after a progesterone challenge test (dydrogesterone 10 mg/day for 10 days).
During the medical examination, patients were specifically asked about their menstrual history. OA was defined as an average cycle length of more than 35 days and included women with frank amenorrhea. Clinical HA was defined by the presence of hirsutism (modified Ferriman-Gallwey score >6) and/or acne located in more than two body areas. Body mass index (BMI) and waist circumference (WC) were also recorded.
Serum levels of prolactin, E2, FSH, LH, TT, androstenedione (A), dehydroepiandrosterone sulfate, 17-OHP, fasting insulin (I), glucose and sex hormone binding globulin (SHBG) were measured as previously described (Dewailly et al., 2006; Robin et al., 2012) . More specifically, serum androgen levels were assessed by radioimmunoassays, as previously reported (Dewailly et al., 2006) , and biochemical hyperandrogenemia was defined by a level above the 95th percentile of controls with normal cycles, i.e. a serum TT above 0.53 ng/ml and/or a serum A above 2.07 ng/ml (Dewailly et al., 2006) . AMH levels were assessed by the secondgeneration enzyme immunoassay AMH-EIA (ref. A16507), provided by Beckman Coulter Immunotech (Villepinte, France) as described previously (Dewailly et al., 2006 (Dewailly et al., , 2011 .
All ultrasound examinations were performed with a Voluson E8 Expert (General Electric Systems, VELIZY, France) with a 5-9 MHz transvaginal transducer. Ultrasound measurements were taken in real time, according to a standardized protocol. The highest possible magnification was used to examine the ovaries. After determination of the longest medial axis of the ovary, the width was measured and the ovarian area was calculated as described previously (Balen et al., 2003; Jonard et al., 2005) . For each ovary, the total number of all visible follicles smaller than 10 mm in diameter was counted by slow and continuous scanning of the entire ovary, from one margin to the other in longitudinal cross-sections. For the ovarian area and the follicle number, the data used for statistical analysis were the means of the recorded values for the left and right ovaries.
Statistical methods
All statistical analyses were performed with SPSS software (SPSS Inc., Chicago, IL, USA). Categorical variables and frequencies were compared by the chi-square test with post hoc analysis when more than two groups were compared. Continuous variables were expressed as medians and 5th-95th percentiles. Because of the non-Gaussian distribution of continuous variables, comparisons between two groups were performed by the non-parametric Mann-Whitney test. Continuous variables were compared between more than two groups with non-parametric ANOVA after rank transformation by the methodology suggested by Conover and Iman (Conover and Iman, 1982) . If the non-parametric ANOVA comparison was significant, each group was compared to others in a post hoc analysis with Bonferroni correction. P values less than 0.05 were considered significant.
Results
Application of the standard Rotterdam classification to our database diagnosed 612 women with PCOS, according to our in-house U/S thresholds for PCOM (see Materials and Methods). When we replaced the U/S definition of PCOM by an excessive AMH level (i.e. >35 pmol/l), PCOS was diagnosed in 601 women. Finally, application of the combination criterion 'positive U/S' and/or 'positive AMH' selected 639 patients with PCOS. The general characteristics of the combined population are presented in Table I. U/S and serum AMH determinations of PCOM were discordant in 103 patients (16.1%) in this population. A high AMH level (i.e. >35 pmol/l) was absent slightly more often than U/S-diagnosed PCOM, but the difference was not significant (9.1% vs. 7%, respectively, P = 0.159). Comparison of the groups positive by U/S-only (n = 58) and by AMH-only (n = 45) indicated that the serum LH levels were significantly higher in the AMH-only group (P = 0.008).
Conversely serum insulin levels tended to be higher in the U/S-only group (P = 0.065). The other variables studied did not differ significantly between the two groups.
The combined (i.e. positive U/S and/or positive AMH) PCOS population was then divided into the four phenotypic groups (Fig. 1) according to the NIH 2012 extension of the Rotterdam classification (National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3-5, 2012. Executive summary available at https://prevention.nih.gov/docs/programs/pcos/ FinalReport.pdf): group A (OA+HA+PCOM), group B (OA+HA), group C (HA+PCOM) and group D (OA+PCOM). As shown in Fig. 2a , we observed that phenotype B almost disappeared (2 cases among 639 women). This group was therefore excluded from subsequent analyses. The prevalence and characteristics of the three remaining phenotypes are shown in Table I . FNPO and serum levels of AMH, LH, TT and A were all significantly lower in both groups C and D than in group A. Serum levels of TT and A were significantly lower in group D than in group C. Groups A and D differed for WC and serum levels of SHBG, but groups A and C did not (Table I) .
The definition of PCOM used (U/S-only, AMH-only, or combined) had no significant influence on the phenotypic distribution within the whole three populations, except for phenotype B (P < 0.0001, Fig. 2 ). Phenotype D tended to be slightly less frequent for the AMH-only definition, but this difference was not significant (Figs 1 and 2c) . Concordance for U/S and serum AMH in defining PCOM was significantly poorer for the mild phenotypes (C and D) than for the full, more severe, phenotype A (Table II) . The percentage of cases with U/S-only PCOM was significantly higher in phenotype D than in phenotype A. In contrast, the percentage of cases with AMH-only PCOM did not differ significantly between the different phenotypic groups (Table II) .
Discussion
Our study found good concordance between AMH serum levels and pelvic U/S results (83.9%) for the diagnosis of PCOM, consistent with previous studies (Dewailly et al., 2011; Iliodromiti et al., 2013) . Although this concordance was not total, we observed no significant superiority of one marker over the other in defining PCOM in our population. This is in contrast to a recent report that the sensitivity of AMH is lower than that of FNPO in diagnosing PCOS (Carmina et al., 2016) . Conversely, several studies reported that the AMH serum level was significantly more sensitive and reliable than FNPO (Dewailly et al., 2011 (Dewailly et al., , 2014a Jeppesen et al., 2013) . It is likely that differences between the study populations and particularly their phenotypic distributions explain these observed discrepancies. The present study, which analyzed a population including all PCOS phenotypes, reconciles these previous results; it shows that excessive serum AMH levels identify almost all U/S false negatives and vice versa. Accordingly, when both markers are applied, phenotype B virtually disappears, despite a prevalence of 2-16% in previous studies that used only U/S data (Dewailly et al., 2006; Welt et al., 2006; Pehlivanov and Orbetzova, 2007; Gluszak et al., 2012; Romualdi et al., 2016; Lizneva et al., 2016) . The dependability of PCOM when defined by the combined criterion may justify its recommendation as a prerequisite for PCOS diagnosis, as proposed two decades ago by Franks (Franks, 1997 ).
False-negative results with either the AMH assay or U/S might explain the discordant findings. However, although this may have happened due to technical issues, the fact that each marker appears to compensate for the other actually suggests that one or the other may be more appropriate for defining PCOM in different subsets of patients with PCOS. This finding might have a pathophysiological basis, as we found significantly higher LH serum levels in the group where PCOM was defined by AMH-only and conversely, a trend to higher fasting insulin levels in the U/S-only group. This is in line with previous clinical studies showing a positive correlation between LH and AMH serum levels in patients with PCOS (Laven et al., 2004; Catteau-Jonard et al., 2007) ; along with experimental data suggesting that this relation results from the stimulating effect of AMH at the hypothalamic level (Cimino et al., 2016) . Conversely, several studies have indicated that hyperinsulinism is correlated with PCOM on U/S (Carmina et al., 2005; Alsamarai et al., 2009 tion. *: in this population, PCOM was defined by using U/S data and/or serum AMH level. For each phenotype, the number of patients that would have been diagnosed as having PCOS if using either U/S or AMH-only to define PCOM is indicated. With these definitions, 612 and 601 patients would have qualified for the diagnosis of PCOS, respectively. HA, hyperandrogenism; OA, oligo-anovulation; PCOM, polycystic ovarian morphology.
AMH serum level and pelvic U/S would likely increase diagnostic sensitivity by identifying those cases of PCOS in which the influence of either LH or insulin is more prominent.
This hypothesis could also explain the greater discordance of these PCOM markers in our patients with the mild phenotypes C and D than in those with the full phenotype A. This is line with previous studies showing by discriminant analysis that an excess number of follicles at U/S is the strongest predictor of OA, while AMH and the AMH/ FNPO ratio are weaker Alebic et al., 2015) . In any case, the phenotypic distribution in the entire PCOS population did not change significantly with U/S-only or AMH-only data. Thus, in a cost-effectiveness approach, either of these two markers of PCOM can be used. Either might be accompanied by the risk of missing cases with either phenotype C or D, which would therefore be considered as either idiopathic HA or OA, respectively. This has no major shortterm consequences, however, because both entities are managed in the same way as genuine 'mild' PCOS. In addition, concern about missing long-term complications of PCOS in those cases is small because patients with genuine PCOS phenotypes C and D have been shown to be at lower risk of metabolic and cardiovascular complications than phenotype A (Moran and Teede, 2009, Lizneva et al., 2016) .
The choice of appropriate threshold for each marker remains unclear (Dewailly et al., 2014a,b) . In this study, we used in-house thresholds based on a previous report (Dewailly et al., 2011) . While it appears unrealistic to expect a consensual threshold for FNPO in the near future, consensus AMH threshold may be possible sooner, thanks to the advent of automated assays for which results should be more consistent from one center to the other. In this study, we used a manual AMH assay that is no longer commercially available. However, this assay is highly reliable, and we recently showed that its results are closely correlated to those produced by the new automated assays (Pigny et al., 2016) . Therefore, we believe that the AMH assay is more likely than U/S to serve as a consensus definition of PCOM in the near future, although with a different threshold than that used here.
The strengths of the study include the size of our PCOS population and its consideration of all PCOS phenotypes. However, the prevalence of phenotype D (28%) was greater than reported by others (Lizneva et al., 2016) , likely because of a referral bias. On the other hand, other biases may have occurred due to the retrospective and single-center nature of the study. The data were nonetheless collected prospectively, with the same U/S device and the same AMH assay for all women.
To conclude, ideally, both the AMH assay and pelvic U/S should be used to determine the presence of PCOM, as their combined use causes the nearly disappearance of phenotype B. From a costeffectiveness perspective, however, use of one or the other of these FNPO < 19 and ovarian area < 5.5 cm 2 and AMH < 35 pmol/l 0% 100% 0% 0%
Overall significance (P) was <0.002. Each group was compared to the two others by the chi-square test with post hoc analysis. For each line, the difference between two groups is significant (P < 0.05) when exponents to the number in % ( PCOM markers has little influence on the diagnosis of PCOS or the distribution of its different phenotypes according to the Rotterdam criteria. Phenotype D tended to be slightly less frequent when PCOM was detected by AMH-only, but this difference was not significant. Although the percentage of cases positive by U/S-only was significantly higher in phenotype D than in phenotype A, this difference had no significant impact on the overall distribution of phenotypes among the whole population. Therefore, the choice of marker depends on local facilities. Given that U/S is a routinely performed test in infertility settings and that in our hands the AMH assay only improved slightly the detection of PCOS cases, the issue of their interchangeability might seem irrelevant. However, it must be emphasized that many centers do not use appropriate thresholds for FNPO (Dewailly et al., 2014b) . Furthermore, in other settings, including endocrine and pediatric units and in countries where primary care units are sometimes far from hospitals and clinics, it is easier and less expensive to draw and ship a blood sample than it is to send the woman to a facility with trained ultrasonographers equipped with the newest generation U/S machines.
